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To maintain a persistent infection viruses such as hepatitis C virus (HCV) employ a 
range of mechanisms that subvert protective T cell responses. The suppression of 
 antigen-specific T cell responses by HCV hinders efforts to profile T cell responses 
during chronic infection and antiviral therapy. Conventional methods of detecting 
antigen-specific T cells utilize either antigen stimulation (e.g., ELISpot, proliferation 
assays, cytokine production) or antigen-loaded tetramer staining. This limits the ability 
to profile T cell responses during chronic infection due to suppressed effector function 
and the requirement for prior knowledge of antigenic viral peptide sequences. Recently, 
high-throughput sequencing (HTS) technologies have been developed for the analysis 
of T cell repertoires. In the present study, we have assessed the feasibility of HTS of 
the TCRβ complementarity determining region (CDR)3 to track T cell expansions in 
an antigen-independent manner. Using sequential blood samples from HCV-infected 
individuals undergoing antiviral therapy, we were able to measure the population fre-
quencies of >35,000 TCRβ sequence clonotypes in each individual over the course 
of 12  weeks. TRBV/TRBJ gene segment usage varied markedly between individuals 
but remained relatively constant within individuals across the course of therapy. Despite 
this stable TRBV/TRBJ gene segment usage, a number of TCRβ sequence clonotypes 
showed dramatic changes in read frequency. These changes could not be linked to 
therapy outcomes in the present study; however, the TCRβ CDR3 sequences with the 
largest fold changes did include sequences with identical TRBV/TRBJ gene segment 
usage and high junction region homology to previously published CDR3 sequences from 
HCV-specific T cells targeting the HLA-B*0801-restricted 1395HSKKKCDEL1403 and HLA-
A*0101-restricted 1435ATDALMTGY1443 epitopes. The pipeline developed in this proof of 
concept study provides a platform for the design of future experiments to accurately 
address the question of whether T cell responses contribute to SVR upon antiviral ther-
apy. This pipeline represents a novel technique to analyze T cell dynamics in situations 
where conventional antigen-dependent methods are limited due to suppression of T cell 
functions and highly diverse antigenic sequences.
Keywords: T cell receptor, high-throughput sequencing, complementarity determining region 3, hepatitis c virus, 
TRBV, TBRJ, clonotype expansion
FigUre 1 | Model of T cell responses and Tcrβ dynamics. (a) Antigen- 
specific T cell clones expand in response to foreign antigen and then contract 
to a stable memory T cell population. (B) Hypothesized TCRβ sequence 
clonotype changes in naive/non-specific versus antigen-specific T cells.
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inTrODUcTiOn
The importance of T cell populations as mediators of protective 
immunity is well documented for a range of viral infections (1–3). 
To maintain a persistent infection viruses such as hepatitis C virus 
(HCV) employ a range of mechanisms that subvert these protec-
tive T cell responses. These include escape from immune pres-
sure, exhaustion of immune cells, and suppression of immune 
pathways. Host genetic studies have identified strong associations 
between specific class I and II human leukocyte antigens (HLA), 
which present viral peptides to T cells, and spontaneous viral 
clearance (4, 5). However, the role of T cell responses in indi-
viduals with chronic infection is less clear. The reversion of viral 
escape variants to consensus sequences upon immune suppres-
sion highlights the fact that HCV-specific T cells actively exert 
immune pressure during persistent infection (6). Furthermore, 
studies have indicated that HCV-specific T cell proliferation and/
or interferon (IFN)γ production can predict sustained virological 
response (SVR) upon treatment, although the evidence for this is 
conflicting (7–12).
Defining the role of HCV-specific T cells during both chronic 
infection and antiviral therapy is challenging due to limitations 
inherent in the experimental assays used to identify HCV-specific 
T cells. Conventional methods of detecting antigen-specific 
T  cells utilize two basic techniques: (1) antigen stimulation 
(e.g., ELISpot, proliferation assays, and flow cytometry) and (2) 
antigen-loaded tetramer staining. Antigen stimulation assays rely 
on a functional readout of T cell activity, however, chronic HCV 
infection and exogenous IFNα used during antiviral therapy are 
both associated with suppressed T cell function. This causes dif-
ficulty when assessing T cell responses in these groups of patients. 
Both antigen stimulation and tetramer staining also rely on 
prior knowledge of the specific antigenic peptides against which 
immune responses are directed. For a hugely diverse pathogen 
such as HCV, this means that even within a single-infected indi-
vidual, it is unfeasible to profile immune responses targeting all 
antigenic sequence variants.
During viral infection, antigens from viral proteins, presented 
by host HLA molecules, are recognized by naive T cells expressing 
antigen-specific T cell receptors (TCR). This recognition results 
in T cell activation, which together with co-stimulation signals, 
leads to the clonal expansion of viral-specific T cells that express 
cytokines and cytotoxic mediators to facilitate pathogen clearance. 
Following clearance of the invading pathogen, this clonal popula-
tion of effector T cells (Teff) contracts and a proportion of these 
cells develop into memory T cell populations, which can persist 
for a number of years and can rapidly respond upon subsequent 
re-challenge with the same antigen (13). Throughout this process 
the antigen-specificity of any particular T cell clone is defined by 
the unique TCR expressed by the parent naive T cell (as illustrated 
in Figure 1A). While this is a simplified model of T cell responses, 
it forms the basis of our theoretical knowledge of how T cells 
respond to a specific antigen and suggests that it should be pos-
sible to utilize sequential TCRβ sequence clonotype size as a proxy 
for clonal expansion and contraction of antigen-specific T cells 
during infection in an antigen-independent  manner (Figure 1B).
The TCR expressed by conventional T cells is composed of 
a heterodimer of a single alpha and beta chain (14). This allows 
recognition of cognate antigen presented by HLA molecules, 
activating the T cell and inducing the development of an adap-
tive immune response. During the development and maturation 
of naive T cells, the TCR gene locus undergoes RAG-mediated 
recombination of the germline V and J gene segments (in the 
case of alpha and gamma receptor chains), or V, D, and J gene 
segments (in the case of beta and delta receptor chains) to pro-
duce a functional rearranged TCR genome locus (14, 15). This 
rearrangement process results in a novel V–J or V–D–J junction 
region, and gives rise to an estimated theoretical TCRαβ reper-
toire diversity of 1018 in humans, which then undergo thymic 
selection (16). In the case of the TCRβ chain, the rearrangement 
involves an estimated 47 possible V regions, two possible D 
regions, and 13 possible J regions (15). This hypervariable junc-
tion region, formed via gene segment rearrangement, is known 
as the complementarity determining region (CDR)3 and is the 
most diverse region defining the peptide-binding properties of 
the TCR.
Recently, high-throughput sequencing (HTS) technologies 
have been developed for the analysis of CDR3 recombination 
events, enabling analysis of T cell populations with unprecedented 
detail. In the present study, we have assessed the feasibility of HTS 
of the TCRβ CDR3 region to track temporal changes in T cell 
populations in HCV-infected individuals undergoing antiviral 
therapy, a setting where conventional T cell assays are limited 
due to antigenic variation and T cell immune suppression. We 
describe a pipeline to identify expanding and contracting T cell 
clones from sequential blood samples and highlight the potential 
and pitfalls of HTS-based techniques to study T cell responses 
during infection.
Abbreviations: CDR, complementarity determining region; HLA, human 
leukocyte antigen; HTS, high-throughput sequencing; IFN, interferon; PBMC, 
peripheral blood mononuclear cells; TCR, T  cell receptor; Teff, effector T cells; 
SVR, sustained virological response.
TaBle 1 | clinical and treatment data.
gender age  
(years)
source of 
infection
gt Fibroscan  
(kPa)
il28B 
genotype
Previous treatment  
agent
Previous treatment 
response
rVr 6-month 
sVr
Pi
Pt 1 M 31 IVDU 3 6.4 CT N/A N/A Y Y N/A
Pt 2 M 51 Blood transfusion 1 5.4 CT IFNα and Ribavirin Non-responder N Y Boceprevir
Pt 3 F 28 IVDU 3 5.2 nd N/A N/A Y Y N/A
Pt 4 M 65 IVDU 1 21.1 CT IFNα and Ribavirin Relapse N Y Telaprevir
Pt 5 M 43 IVDU 3 4.8 nd N/A N/A Y Y N/A
Pt 6 M 44 IVDU 1 4.5 CT PEGylated IFNα and 
Ribavirin
SVR with reinfection Y Y Telaprevir
Gt, viral genotype; nd, not done; N/A, not applicable.
3
Robinson et al. Tracking TCRβ Expansions via HTS
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 131
MaTerials anD MeThODs
clinical Data
Clinical samples were used with informed consent, conforming 
to the ethical guidelines of the 1975 Declaration of Helsinki and 
study protocols were approved by the West of Scotland Research 
Ethics Committee. Blood samples were obtained from chronically 
HCV-infected patients who were beginning antiviral therapy as 
part of a larger clinical cohort (17). Blood samples were taken 
pre-treatment, and at weeks 1, 2, 4, and 12 following the initia-
tion of PEGylated IFNα and ribavirin therapy. Six patients were 
included in the study: three patients infected with HCV genotype 
1 and three patients infected with HCV genotype 3 (as detailed 
in Table  1). All patients were initially treated with PEGylated 
IFNα and ribavirin, with the HCV genotype 1-infected individu-
als also receiving a protease inhibitor from week 4 of therapy. 
Four patients showed a rapid virologic response (RVR) with 
viral loads ≤50 IU/mL within 4 weeks, of whom two achieved 
this reduction within 2 weeks. Two patients (both infected with 
HCV genotype 1) showed little decline in viral load in response 
to PEGylated IFNα and ribavirin but cleared the virus by week 
12 following the initiation of a protease inhibitor after week 4. 
All patients successfully cleared the virus following the comple-
tion of their treatment and all patients were classified as SVR at 
6 months following the end of treatment.
amplification of the Tcr cDr3 region 
from Peripheral Blood Mononuclear cells
DNA-free total RNA was extracted from peripheral blood 
mononuclear cells (PBMCs) and reverse transcribed using the 
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, Life 
Technologies, Paisley, UK). RNA quality was assessed on an 
Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, 
CA, USA), prior to reverse transcription. To amplify the TCR 
CDR3 region, a previously published set of primers was utilized 
consisting of 45 forward primers, each specific to a functional 
T cell receptor beta variable (TRBV) gene segment, and 13 
reverse primers, each specific to a T cell receptor beta joining 
(TRBJ) gene segment (18). Duplicate PCR reactions were set up 
using the QIAGEN® Multiplex PCR kit (Qiagen, Manchester, 
UK), including 10% Q-solution, and pooled prior to library 
preparation.
library generation and sequencing
PCR amplicons were washed, purified, and size-selected using 
Agencourt® Ampure® XP beads (Beckman Coulter, High 
Wycombe, UK) and subsequently quantified on a Qubit® 2.0 
Fluorometer using the Qubit® dsDNA High Sensitivity kit 
(Invitrogen). Library preparation, including end repair, A-tailing, 
and adaptor ligation, was performed using the KAPA HiFi Real-
Time PCR Library Amplification kit for Illumina libraries (KAPA 
Biosystems, Wilmington, MA, USA). The A-tailed PCR amplicons 
were ligated to NEBNext® Multiplex Oligos for Illumina® (New 
England Biolabs, Ipswich, MA, USA) and end repair of the forked 
adaptors was carried out using either Index Primer Set 1 or 2 (New 
England Biolabs). Adaptor ligated products were quantified using 
the KAPA SYBR® FAST ABI Prism qPCR library quantification kit 
(KAPA Biosystems). Sequencing was performed using an Illumina 
MiSeq™ System Desktop Sequencer (Illumina, San Diego, CA, 
USA), with a 300 cycle MiSeq version 2 reagent kit (Illumina). To 
avoid errors due to low sequence diversity within the PCR ampli-
cons the libraries were sequenced with a 25% PhiX spike-in, at a 
low cluster density (~800 K/mm2), and run metrics were checked 
to ensure that 85–90% of clusters passed quality filtering.
Tcr sequence analysis
Raw sequencing reads were trimmed, to remove poor quality 
sequence and adaptor sequences, using fastq-mcf 1 and Trim 
Galore 2. The paired-end reads were then joined using fastq-join 3. 
The remaining filtered and joined sequence reads were analyzed 
using the pipeline summarized in Figure  2. Briefly, reads were 
assigned a unique identifier and the TRBV and TRBJ primer 
sequences were analyzed using custom perl scripts (SeqRenamer.
pl and PrimerTrim.pl). The PrimerTrim.pl script trims the 
primer sequences from the reads, identifies reads lacking primer 
sequences, and outputs TCR Vβ and Jβ usage. Sequences lack-
ing a TRBV or TRBJ primer pair or containing two TRBV or 
TRBJ primer sequences were removed using custom perl scripts 
(RemoveSamePrimer.pl and FastqFilter.pl), and a gene usage 
text file was generated from the PrimerTrim.pl output (using 
ParseStats.pl). The .fastq sequencing files were converted to .fasta 
1 https://code.google.com/p/ea-utils/wiki/FastqMcf
2 http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/
3 https://code.google.com/p/ea-utils/wiki/FastqJoin
TaBle 2 | sequencing filtering and clustering statistics.
Total reads Joined reads passing 
filtering
% reads passing 
filtering
singletons % singletons Tcrβ sequence 
clonotypes
clonotypes >0.0001 
read frequency
Pt 1 day 0 712,114 578,962 81.30 138,579 23.94 96,342 351
Pt 1 day 14 634,288 509,817 80.38 123,369 24.20 86,115 309
Pt 1 day 28 678,888 541,744 79.80 131,904 24.35 91,304 273
Pt 1 day 84 729,463 587,775 80.58 129,391 22.01 94,690 351
Pt 2 day 0 757,735 605,308 79.88 59,620 9.85 53,696 649
Pt 2 day 14 780,672 634,618 81.29 53,667 8.46 45,556 735
Pt 2 day 28 719,236 582,503 80.99 48,491 8.32 37,518 889
Pt 2 day 84 794,255 619,977 78.06 48,074 7.75 35,749 1,056
Pt 3 day 0 730,970 568,087 77.72 142,900 25.15 102,441 202
Pt 3 day 14 742,921 603,994 81.30 62,924 10.42 57,993 380
Pt 3 day 28 715,794 591,947 82.70 161,392 27.26 109,160 168
Pt 3 day 84 679,172 535,881 78.90 162,876 30.39 98,310 168
Pt 4 day 0 805,599 636,395 79.00 112,244 17.64 71,884 729
Pt 4 day 14 705,899 568,716 80.57 50,552 8.89 41,283 820
Pt 4 day 28 434,032 346,336 79.80 79,450 22.94 47,085 590
Pt 4 day 84 677,674 528,767 78.03 81,657 15.44 67,809 661
Pt 5 day 0 706,399 572,666 81.07 174,381 30.45 94,164 335
Pt 5 day 14 751,609 606,642 80.71 119,104 19.63 94,296 315
Pt 5 day 28 806,787 641,859 79.56 111,678 17.40 97,188 288
Pt 5 day 84 692,772 545,476 78.74 129,638 23.77 91,356 274
Pt 6 day 0 853,716 660,961 77.42 201,954 30.55 111,499 269
Pt 6 day 14 838,230 666,127 79.47 146,402 21.98 111,654 246
Pt 6 day 28 764,235 630,828 82.54 148,399 23.52 113,641 210
Pt 6 day 84 840,148 677,297 80.62 103,453 15.27 100,277 228
FigUre 2 | Flow chart of the sequence analysis pipe-line.
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files and identical reads were grouped into TCRβ sequence clo-
notypes using cd-hit-est (19). For the cd-hit-est step the global 
sequence identity threshold was set to 100%, the word size was set 
at 10, and sequences were aligned in both directions. The output 
files were parsed using a perl script (sort_cdhit.pl) to extract the 
number of reads for each TCRβ sequence clonotype, filter on 
the basis of read frequency and output a representative sequence 
for each TCRβ sequence clonotype. To explore TCRβ sequence 
clonotypes between different samples, the output files from the 
sort_cdhit.pl script from two or more samples were concatenated 
and analyzed using cd-hit-est a second time. The output files were 
parsed using a perl script (Count_clstr.pl) to generate a compari-
son table detailing the TCRβ sequence clonotype number and size 
for each sample. Representative sequences from non-redundant 
TCRβ sequence clonotypes, which were represented by more than 
0.01% of the total reads (equivalent to a frequency of 0.0001), were 
analyzed using IMGT/HighV-QUEST (20) to identify sequences 
with productive CDR3 regions. This cut-off was selected in order 
to reduce the detection of TCRβ sequence clonotypes that arose 
due to sequencing error, the frequency of which was estimated 
from the known primer sequences to range between 0.001 and 
0.003 per nucleotide across the sequencing datasets (data not 
shown). This also had the effect of biasing the TCRβ sequence 
clonotypes toward expanded Teff and memory T cell populations 
as opposed to low frequency naive T cell populations. Output files 
detailing productive sequence frequency for each sample were 
generated using a perl script (ParseIMGT.pl) and final data nor-
malization and visualization was performed in R. All perl scripts 
used are publically available at https://github.com/josephhughes/
TCRclust.
resUlTs
The Tcr repertoire and TrBV/TrBJ  
gene Usage are relatively stable within 
individuals over the First 12 Weeks of 
antiviral Therapy
The results of the TCR sequencing and data processing are sum-
marized in Table  2. Over 400,000 raw paired-end reads were 
obtained for each sample, which resulted in greater than 300,000 
TCR sequences per sample (range 346,336–677,297) after filtering. 
FigUre 3 | high intra-individual similarity in TRBV and TRBJ gene 
segment usage. Distance heatmaps using Manhattan distance measures 
for TRBV (a) and TRBJ (B) gene segment usage calculated from the gene 
segment frequency following the primer trimming step.
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Following the removal of singleton sequences, which likely 
represent sequencing/PCR errors, between 35,000 and 115,000 
TCRβ sequence clonotypes were detected (Table 2). The number 
of TCRβ sequence clonotypes varied markedly between patients 
but was relatively consistent between sampling time points, with 
patients 2 and 4 both having a low total number of TCRβ sequence 
clonotypes across all time points sampled (Table 2). These two 
patients were the oldest in the study (at 51 and 65 years of age), 
which potentially contributed to the reduced TCRβ repertoire 
diversity observed. Both individuals also failed to achieve RVR, 
although both subsequently achieved SVR (Table 1).
In addition to the intra-individual consistency in the total 
number of TCRβ sequence clonotypes, there was a high degree 
of intra-individual similarity in terms of gene segment usage. 
The frequency of TRBV and TRBJ gene segment usage within 
sequence datasets, from each individual patient and time point, 
was used to calculate a distance matrix, using Manhattan distance 
measures, to provide a metric for the similarity in gene segment 
usage between datasets, as visualized for TRBV in Figure 3A and 
for TRBJ in Figure 3B. The TRBV and TRBJ gene segment usage 
was most similar (as indicated by small distance values, visualized 
as dark red colors) between samples collected at different time 
points from the same individual. In contrast, the TRBV and TRBJ 
gene segment usage was less similar (visualized as a shift toward 
dark blue colors) between samples from different individuals. 
The average distance value between intra-individual datasets 
from different time points for TRBV gene segment usage was 
0.093 versus 0.221 for the inter-individual datasets (p < 0.0001; 
Mann–Whitney test). The average distance value between intra-
individual datasets from different time points for TRBJ gene 
segment usage was 0.059 versus 0.146 for the inter-individual 
datasets (p < 0.0001; Mann–Whitney test). In all six patients the 
stability of the TCR repertoire, both in terms of numbers of TCRβ 
sequence clonotypes and of TRBV/TRBJ gene segment usage, is 
maintained despite a significant decrease in circulating lympho-
cytes across the course of therapy (data not shown), as previously 
identified during IFNα-based treatments (21).
Mapping sequential Tcrβ sequence 
Frequencies identifies changing Tcrβ 
sequence clonotypes
To explore changing T cell populations at a level of detail beyond 
TRBV and TRBJ gene segment usage, a pipeline was established 
to compare productive TCRβ sequence clonotypes within indi-
viduals across different time points (Figure 2). In order to avoid 
detection of TCRβ sequence clonotypes arising due to sequencing 
error, and to bias our dataset toward expanded Teff and memory 
T cell populations, we focused on clonotypes with a frequency of 
>0.0001. While the majority of TCRβ sequence clonotypes had 
stable read frequencies across the 12 weeks of antiviral therapy, a 
minority of TCRβ sequence clonotypes showed dramatic changes 
in read frequency (Figure 4). In certain cases, this represented 
a fold change in read frequency of hundreds for individual 
TCRβ sequence clonotypes which either expanded or contracted 
between sequential time points. These dramatic changes within 
specific TCRβ sequence clonotypes are not apparent at the level 
of TCRβ gene segment usage (Figure 3) or the total number of 
TCRβ sequence clonotypes detected (Table 2).
Comparing the four patients with RVR upon PEGylated IFNα 
and ribavirin therapy versus the two patients (patients 2 and 4) 
who only showed a reduction in viral load upon initiation of 
protease inhibitor treatment at week 4, a trend toward increased 
TCRβ sequence clonotype size was noted (Figure  4). The sig-
nificance of this observation in regard to RVR is unclear. Patients 
2 and 4 were the oldest and had lower total numbers of TCRβ 
sequence clonotypes across all time points, which contributed to 
an increase in the size of individual clonotypes when expressed 
as a % of total reads. This limitation in the data highlights one of 
the difficulties in directly comparing TCRβ repertoires between 
patients and necessitates larger, age-matched patient groups in 
future studies.
FigUre 4 | Viral load kinetics and Tcrβ sequence clonotype size during therapy. For each patient, the upper panel details circulating HCV viral load (IU/mL) 
across the first 12 weeks of antiviral therapy, while the lower panel shows matched sequential TCRβ sequence clonotype size (expressed as a % of total reads) for 
the 10 clonotypes showing the greatest expansion at each time-point compared to day 0, from a particular individual. The TCRβ sequence clonotypes highlighted 
with color have ≥80% identity across the junction region with published HCV-specific TCRβ sequences.
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The temporal nature of the TCRβ sequence data allows it 
to be compared to clinical changes over the course of antiviral 
therapy, e.g., viral load, as shown in Figure  4. This facilitates 
the identification of TCRβ sequence clonotypes that show 
frequency changes concurrent with a decline in HCV viral load. 
For patients 3, 5, and 6, dramatic declines in HCV viral load 
are associated with the large expansions of particular TCRβ 
sequence clonotypes (Figure  4). In these three patients, the 
maximum TCRβ sequence clonotype fold increase between 
day 0 and day 14 was 114×, 83×, and 220×, respectively. The 
association with declines in viral load suggests that these TCRβ 
sequence clonotypes may be relevant for viral control in these 
patients and distinguishes these clonotypes from others, which 
show even larger expansions, e.g., the TCRβ sequence clono-
type in patient 4 that expands 742× between day 0 and day 14 
(Figure 4).
TaBle 3 | expanding Tcrβ sequence clonotypes with ≥80% identity to published hcV-specific Tcrβ sequences.
clonotype 
(patient)
Day detected Fold increase TRBV TRBJ Junction sequence Matched 
accession 
% identity Matched 
TRBV/TRBV
670 (pt 1) 14 4.5 7–6, 7–7, or 7–9 2–2 CASSQSQTGNTGELFF ADQ19362.1 81 No
3765 (pt 3) 28 3.9 10–3 2–3 CAISTSGRGTDTQYF ADQ19287.1 87 Yes
9961 (pt 4) 14 23.9 19 2–6 CASSISDSGANVLTF ADQ19329.1 80 No
9052 (pt 4) 28 12.5 28 2–7 CASSLGSGTTYEQYF ADQ19416.1 80 No
2026 (pt 5) 14 83.8 6–1, 6–5, or 6–8 2–2 CASRTGSSDTGELFF ADQ19381.1 87 No
6896 (pt 5) 28 7.1 7–6 2–2 CASSSRTGVNTGELFF ADQ19362.1 88 No
10020 (pt 5) 84 42.0 6–1 2–2 CASRTGSSDTGELFF ADQ19381.1 87 No
372 (pt 6) 14, 84 220.5, 102.5 7–2 1–1 CASSDRDGGWTEAFF ADQ19336.1 80 No
8261 (pt 6) 14, 28 10.7, 5.2 19 1–1 or 1–5 CASSIDQGGNQPQHF ADQ19349.1 80 No
12872 (pt 6) 28, 84 6.6, 7.1 5–6 1–3 CASSLSAGDQPQHF ADQ19293.1 80 No
10041 (pt 6) 28 6.2 19 1–5 CASSIRQARTQPQHF ADQ19349.1 80 Yes
11938 (pt 6) 84 5.7 19 1–5 CASSIDQGGNQPQHF ADQ19349.1 80 Yes
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To explore the possible antigen-specificity of expanding TCRβ 
sequence clonotypes identified in Figure  4, we interrogated 
sequence databases containing information on experimentally 
validated antigen-specific TCRβ sequences. Using BLAST 
searches (blastp) of non-redundant human protein sequences, 
we identified 12 TCRβ sequence clonotypes with ≥80% identity 
to published HCV-specific TCRβ CDR3 sequences (Table  3). 
These HCV-specific TCRβ CDR3 sequences are specific for 
either the HLA-B*0801-restricted 1395HSKKKCDEL1403 epitope 
or the HLA-A*0101-restricted, 1435ATDALMTGY1443 epitope 
(22). Three of the 12 TCRβ sequence clonotypes with ≥80% 
identity to HCV-specific TCRβ CDR3 sequences had match-
ing TRBV and TRBJ gene segment usage (Table 3) and highly 
similar junction regions, differing by two (clonotype 3765) or 
three amino acids (clonotypes 10041, and 11938). This provides 
additional evidence that the expanding TCRβ sequence clono-
types detected in the present study are HCV-specific although 
in the absence of functional validation this is impossible to 
definitively prove.
DiscUssiOn
High-throughput sequencing technologies are revolutionizing 
our understanding of T cell biology. The ability to detect and 
sequence thousands of TCR sequences simultaneously has 
provided detailed understanding of the clonal T cell population 
structure in both health and disease. In this context, techniques 
allowing the integration of TCR sequence data from sequential 
time points provide the possibility to track clonal T cell popu-
lations over time and identify responding T cell populations 
in the absence of prior knowledge of antigen-specificity. This 
is particularly relevant in human diseases where the specific 
antigen driving T cell activation is unknown (e.g., autoim-
munity) or the nature of the infectious pathogen results in 
high inter- and intrahost antigenic variation (e.g., hepatitis C 
virus infection). It is also valuable in settings (such as HCV 
treatment) where T cell numbers and function are suppressed. 
In the present study, we have developed a pipeline for the 
integration of sequential TCR HTS data, allowing analysis of 
multiple sequential datasets each containing over half a million 
sequence reads.
Numerous TCRβ sequence clonotypes expanded and con-
tracted over the first 12 weeks of therapy, despite a lack of gross 
changes in TRBV and TRBJ gene usage over the course of HCV 
antiviral therapy, and the overall stability of the TCRβ repertoire 
within individuals. The clonotype-specific nature of this T cell 
response may contribute to the conflicting data regarding the 
importance of HCV-specific T cell responses during HCV 
therapy (7–12). Diverse T cell repertoires can predict good dis-
ease outcomes in mice infected with herpes simplex virus-1 (23); 
however, it is unclear if this also applies in human disease. A more 
diverse T cell response potentially allows for the selection of high 
avidity T cell clones and limits pathogen immune escape (24). In 
HCV infection, T cell responses are critical in controlling infec-
tion, as evidenced by class I and II HLA associations (25–28), 
CD4+ and CD8+ depletion experiments in the chimpanzee model 
(29–31) and functional assays during early HCV infection (32). 
Studies during acute HCV infection have shown by ELISpot and 
flow cytometry that the T cell response during spontaneous clear-
ance is broad, targets multiple antigens and must be sustained 
for HCV to be eliminated during early infection. However, only 
a single study has sequenced TCR repertoires from functionally 
validated HCV-specific T cells, and this only investigated two 
specific antigenic peptides (22). This small number of validated 
HCV-specific TCRβ CDR3 sequences limits the inferences that 
can be made using a sequence similarity approach as employed 
in the present study. In addition, this similarity approach does 
not prove that the identified TCRβ sequence clonotypes are 
HCV-specific, due to the influence that TCRα pairing and HLA-
restriction have on antigen recognition. This limitation in the 
present study highlights the need to integrate HTS techniques 
with the isolation of antigen-specific T cell populations to enable 
validation of antigen-specific TCR sequences.
Conventional studies of T cell responses during treatment 
are hampered by low numbers of T cells and reduced cytokine 
production, issues avoided when using an HTS approach. 
Evidence of a restoration of HCV-specific T cell populations 
over the course of HCV therapy has recently been obtained in 
patients treated with IFN-free regimes, where individuals who 
achieved SVR had an increased proliferation of HCV-specific 
CD8+ T cells within 4 weeks of starting therapy (33). Due to a 
reliance on HCV-specific tetramers, this study was limited to 
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the analysis of T cells specific for one of four HCV peptides, 
highlighting the limitations imposed by current methodologies. 
Utilizing HTS of TCR sequences in a larger number of patients 
could help to answer fundamental questions on the role of the 
immune response in viral control during and immediately after 
treatment. It may also be of use in acute infection, where many 
current studies require live cells to be available from early in 
infection – a stage which is usually asymptomatic. HTS of TCR 
sequences has the potential to be carried out on stored blood 
samples without the need for PBMC separation. In conjunction 
with functional validation experiments, this would allow for a 
comprehensive analysis of T cell responses in a larger number of 
infected individuals.
The present proof of concept study highlights the large 
inter-individual variation detected in TCRβ sequence clonotype 
structures, which hampers comparisons between individuals in 
this sort of observational study design. In particular, patients 
2 and 4, the two oldest patients in the present study, showed a 
lower total number of TCRβ sequence clonotypes, and a greater 
proportion of TCRβ sequence clonotypes with read frequencies 
>0.0001. This altered repertoire, with evidence of TCRβ sequence 
clonotype expansion, is similar to the T cell repertoire changes 
observed in aging individuals with human cytomegalovirus 
(HCMV) infection (34, 35). Future studies should utilize large 
cohorts of age- and HLA-matched individuals with defined 
treatment outcomes to account for inter-individual variation 
and accurately address the question of whether T cell responses 
contribute to SVR upon antiviral therapy. The pipeline developed 
in the analysis presented here provides a platform for the design 
of these experiments.
To avoid sampling or sequencing biases that may have hindered 
the identification of T cell expansion or contraction, we included 
the use of pooled PCR reactions and a high read frequency cut-off 
for the analysis of TCRβ sequence clonotypes. The use of unique 
molecular identifiers has been recently introduced to limit the 
effects of PCR bias in HTS experiments and this technique offers 
significant advantages to the analysis of future HTS studies of 
the TCR locus (36, 37). Sampling bias  –  arising from the fact 
that we can only sample a fraction of an individual’s total T cell 
pool  –  is more difficult to address. This issue is of particular 
relevance for low frequency T cell clones and maintaining a high 
read frequency cut-off can help to avoid sampling bias. Sampling 
bias is well recognized in the field of population ecology where a 
number of techniques have been developed to control for these 
biases, and the application of these methods to HTS should be 
expanded in the future (37, 38).
In summary, the analysis of T cell responses through HTS 
techniques has the potential to greatly expand our understanding 
of the role of T cells in health and disease. The development of 
sequential analysis of TCRβ sequence clonotypes can provide an 
antigen-independent view of T cell dynamics in complex tissue 
environments, complementing existing T cell phenotyping assays, 
and providing insights into the role of immunological diversity in 
protection from infectious disease.
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